CHAPEL HILL, N.C., Oct. 9 /PRNewswire/ -- Pharmaceutical and biotech companies reach much greater and sustained product success when they ensure strong partnerships between R&D and marketing, balancing therapeutic innovation with commercial focus in all stages of product development.
It requires companies to break down the walls that have traditionally separated R&D from marketing and instead leverage the strengths of both talented medical researchers and skillful marketers.
Best Practices LLC's benchmarking report, "Best Practices in Global Pharmaceutical Launches," outlines just what commercially focused R&D looks like.
Analysts harvested survey data and qualitative best practices from informed executives at elite pharmaceutical companies, including Merck, Pfizer, Johnson & Johnson, Bristol-Myers Squibb and Novartis. The report includes over 180 metrics, 100 best practices and 20 company narratives on critical pre and post launch topics, including:
* Marketing Launch Strategy and Structure
* Marketing Investment and Staffing
* Cross-Functional Launch Team Composition and Management
* Thought Leader Development
* Sales Force Support and Compensation Management
* Market Research
* Marketing Activities
* Life Cycle Management
For more information, sample practices and graphics from this report, download a complimentary excerpt at http://www3.best-in-class.com/rr864.htm.
Example best practices from the report include:
* The most successful product launches reveal new levels of organizational
alignment. Marketers play a vital role in shaping and planning product
strategy. Marketing activities are beginning earlier in the development
process - often four to six years prior to launch.
* Top-performing benchmark partners invested significant financial and
human resources to en
|SOURCE Best Practices LLC|
Copyright©2007 PR Newswire.
All rights reserved